were kindly provided by Merck KGaA (Darmstadt, Germany). Cadaverine, dextran from leuconostoc mesenteroides (average Mol. Wt. 9000-11000), N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), SYPRO Orange and 2-azidoacetic acid were purchased from Sigma-Aldrich. Di-tert-butyl dicarbonate was purchased from Carbolutions (St. Ingbert, Germany), and dispase -from Cellsystems (Troisdorf, Germany).
For immune-staining Alexa-Fluor© 488 AffniPure Fab Fragment specific for human IgG (H+L) was obtained from Jackson ImmunoResearch, and goat anti-human IgG Fc PE eBioscience™ -from Fisher Scientific (Hampton, USA).
Mass spectrometry
Electrospray ionization mass spectrometry (ESI-MS) spectra were obtained using a 
NMR spectroscopy
NMR measurements were recorded on an Avance III or an Avance II NMR Spectrometer at 300 MHz (Bruker BioSpin GmbH, Rheinstetten, Germany). Samples were dissolved in chloroform-d or deuterium oxide from Sigma Aldrich Chemie Gmbh (Munich, Germany, now Merck KGaA, Darmstadt, Germany).
IR spectroscopy
IR measurements were performed using homogenous potassium bromide pellet on a FTIR-Spectrometer Spectrum Two (PerkinElmer, Rodgau, Germany). Spectra were obtained by PerkinElmer Spectrum following instructions of manufacturer. Wave number area: 8.300-350 cm -1 , spectral solution 0.5 cm -1; , wave number accuracy better than 0,01 cm -1 at 3.000 cm -1 ; wave number correctness: 0,1 cm -1 at 3.000 cm -1 ; signal-tonoise-ratio: 9.300 : 1 Peak to Peak, 5 s and 32.000 : 1 Peak to Peak, 1 min.
Quantification of carboxyethyl groups per dextran using 1 H-NMR
Quantification of carboxyethyl (CE) groups per Dextran was determined as previously described. [1] A quantification using titration was not performed, since NMR analysis showed similar results. [1] Briefly: The ratio of integrals corresponding to the anomeric proton of glucose repeating units to the signals corresponding to the C2-position of the carboxyethyl group (CE-group) was used to determine the number of CE groups per dextran via 1 H-NMR. [1] Richter et al. showed by 2D-NMR analysis, that carboxyethylation following the procedure used in this work only took place at C2 position of the glucose of repeating units. [1] An example for quantification is shown in Figure S1 (for further NMR data see Section 1.3.5). Signal 1 corresponds to anomeric protons of glucose repeating units, whereas signal 2 corresponds to the two protons at the C2 of the integrated carboxyethyl groups. The ratio of CE-groups per dextran was calculated using formula (1)
(1) substitution of 4.5, 8.5 and 11 CE groups per dextran was found for compound 4, 5, and 6. The degree of substitution was adjusted from 4.5 to 25 (data not shown). About 40 % of the applied acrylamide was conjugated to the glucose repeating units in all experiments (Table S1) . A higher density of CE groups per dextran was achieved using a smaller dextran (Mw =5000) with only 31 glucose repeating units (24 CE groups/dextran, Figure S2 ). 
Detection of N3-groups via IR spectroscopy and quantification using NMR spectroscopy
IR spectroscopy was used for the detection of the coupling of azido linker 2 to compounds 4, 5, and 6
( Figure S3 ). The band corresponding to the N3 group of compound 10, 11, and 12 is found at 2120 cm -1 and does not superimpose with any band found in the dextran IR spectra. [2] Therefore the intensity of this band gives a first evidence for azide modification of dextran. As expected, an increasing intensity of the N3 band was observed for compounds 10, 11, and 12 with increasing numbers of possible conjugation sites ( Figure   S3 ). Thereupon quantitative determination was performed utilizing 1 H-NMR spectroscopy ( Figure S4 ). Integrals corresponding to the aliphatic protons of azido linker 2 were quantified and compared to the signals corresponding to the C2-protons of the CE group. A quantitative N3-modification of previously introduced carboxyethyl groups was observed for all compounds ( Table 2 , for further NMR data see section 1.3.5). 7, 10 8, 11 9, 12 N3-groups/ dextran 4.5 8.5 11
Liquid chromatography
Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on either an 
Hydrophobic interaction chromatography (HIC)
Analytical hydrophobic interaction chromatography (HIC) was performed on an Agilent Infinity 1260 equipped with a Tosoh Bioscience TSKgel Butyl-NPR (2.5 µM, 4.6 mm×3.5 cm) using a linear gradient 0 to 100% B in 45 min (Eluent A: 1.5 M ammonium sulfate and 25mM TRIS-HCl pH 7.5. Eluent B: 25mM TRISHCl pH 7.5). Prior to analysis the constructs were diluted with 3 M ammonium sulfate to a final concentration of 0.75 M ammonium sulfate. Analysis of all generated dextramabs 20 -23 (and therefore also all azidemodified precursors 14 -16) showed that at least 1 dextran was conjugated per trastuzumab, since no signal of unmodified trastuzumab-LLQG 13 was detected (Figure 2 ).
Cell culture
Cell lines were incubated under standard conditions at 37 °C in a humidified incubator with 5 % CO2. SK-BR-3 breast cancer cells were grown in DMEM culture medium with 10 % FBS. CHO-KI cells were grown in DMEM F-12 HAM with 10 % FBS. Expi293F™, a non-adherent cell line, was obtained from Thermo Fisher
Scientific and was grown in serum-free Expi293™ expression medium on an orbital shaker at 110 rpm.
Protein expression and purification
Trastuzumab LLQG was produced by transient transfection of Expi293™ with the respective pTT5 and pEXPR plasmid using polyethylenimine (PEI). The LLQG mTG recognition tag was added to the C-terminus of the heavy chain using standard PCR procedure. 30 µg of the corresponding plasmid were mixed with 90 µg of PEI in serum-free Expi293™ expression medium and added dropwise to 30mL of Expi293 TM cells, in a density of 2.5×10 6 cells/mL, under continuous shaking. After 24 hours the cells were fed with 0.5 % (w/v) tryptone. After 120 h the cell supernatant was purified by protein A affinity chromatography using HiTrap Protein A HP columns (GE Healthcare), A 1:1.5 dilution of antibody production supernatant in running buffer (20 mM sodium phosphate, pH 7) was applied to the column after its equilibration with running buffer.
Elution was carried out using 100 mM citrate buffer pH 3. The eluate was dialyzed and concentrated using an Amicon Ultra centrifugation filter.
Inactive pro-microbial transglutaminase was produced as previously described. (final concentration 500 µM) cells were incubated at 24 °C and 180 rpm for 3 h. Cell lysis was accomplished using a Constant Systems Ltd cell disruptor (Daventry, UK). Purification was performed using standard IMAC purification on a HisTrap HP (GE Healthcare) column. Purified pro-mTG was stored in mTG storage buffer (20µg dispase/mg pro-mTG; 300 mM NaCl, 50 mM TRIS-HCl pH 8, 5 mM CaCl2, 1 mM glutathione (reduced)).
Activation of pro-microbial transglutaminase
pro-mTG was activated upon addition of bacillus polymyxa neutral protease (dispase) dissolved in mTG storage buffer. After incubation at 37 °C for 30 min, purification was performed using standard IMAC procedure on a HisTrap HP (GE Healthcare) column. Purified mTG was stored in mTG storage buffer + 10 % glycerol at -80 C.
Thermal shift assay
Thermal shift assays were performed in triplicates on a BioRad96CFX RT-PCR detection system with 0.5 °C/30 s to 99 °C. Tm values were collected from melting curves using the corresponding BioRad analysis software ( Figure S5 ). All reactions were performed in 1 × PBS pH 7.4 at a concentration of 0.1 mg/mL protein upon addition of SYPRO Orange (diluted 1:800). 
Cellular binding
Human cancer SK-BR-3 cells were trypsinized from the culture flask and spun down. Cells (2 x 10 5 ) were washed three times with 1× PBS pH 7.4 containing 1% bovine serum albumin (BSA) followed by incubation with the respective dextramab-MMAE/Cy5 or the unconjugated trastuzumab-LLQG 13 (100 µl, 0.1mg/mL in 1× PBS, pH 7.4, 1% BSA) for 10 min on ice. Constructs 22 and 13 were used for cellular binding assays. 
Determination of KD by flow cytometry
Human cancer SK-BR-3 cells were trypsinized from the culture flask and spun down. Cells were counted and 
Photometric control of strain-promoted azide-alkyne cycloaddition (SPAAC) and determination of fluorophore-to-antibody ratio (FAR)
The concentration of the Cy5-modified dextramab 18 was determined by standard OD280 measurements. A calibration curve for DBCO-Cy5 17 was measured at 661 nm on a Shimadzu UVmini-1240 UV-VIS spectrophotometer (Table S3) . For all measurements at least a triple determination was conducted ( Figure   S8 ). Three equivalents of DBCO-Cy5 17 were conjugated to azide modified construct 15 to obtain construct 18, which was used for the control of quantitative coupling and measured in three different dilutions (Table S4) . (1)
A quantitative "click" coupling was preserved for SPAAC of DBCO-Cy5 18 and construct 15. Figure S9 ). Cell viability was measured using CellTiter96® AQueous One Solution Cell
Cytotoxicity assay
Proliferation Assay (Promega) following the instructions of the supplier using a Tecan © Infinite F200 Pro.
As comparison a classical DAR 2 ADC 25 was used. Construct 25 showed an IC50 value of 0.218 nm whereas dextramab 22 was found more potent with an IC50 value of 0.10 nm. As non-binding control an antibody Calibration Curve Cy5 17 comprising the light chain of matuzumab and the heavy chain of trastuzumab equipped with an mTG recognition tag was used. No toxicity was found for the isotype control ( Figure S9 ). An example for SDS-PAGE and HIC-analysis is shown in Figure S11 . Constructs 14, 15 and 16 were generated bearing at least 4.5, 8.5 respectively 11.5 N3-groups per antibody (at least one dextran per antibody coupled, see chapter 1.1.8; Figure 1 ; Figure S11 ). Construct 24 with only the linker 2 coupled showed no complete consumption of the amine substrate, as three different peaks are visible in HIC analysis ( Figure S12 ). However it was used for "click" reactions.
Hence, linker 2 seems to be a poor mTG substrate, trastuzumab-LLQG 13 could neither be modified quantitatively with constructs 14 -16, nor directly with linker 2 in this set-up. Since compound 24 was only generated as precursor of MMAE-loaded construct 25, to get access of HIC date for a DAR 1 and DAR 2 trastuzumab, no further improvements of enzymatic conjugation were carried out. -promoted azide-alkyne cycloaddition (SPAAC) of dextramab or N-(5-aminopentyl) For SPAAC the respective compound (14, 15, and 16) equipped with azide groups or N3-mAb, 24 was diluted to a final concentration of 2-5 mg/mL in 1×PBS pH 7.4 in the respective equivalents (Table S5) Figure   S15 ). Construct 25 showed a mixture of DAR 1-2 as explained in section 1.2.1 ( Figure S15 ). Both the DAR 1 and the DAR 2 species showed an hydrophobic shift as the retention time on the HIC column shifted to 25.1 respectively 32.3 minutes compared to trastuzumab-LLQG 13 which was found at 16.8 min. In contrast all dextramab compounds (DAR 2-11) 20 -23 were found at retention times between 12 and 19 minutes.
Strain
Construct 18 was used for the control of SPAAC (Section 1.1.15) To estimate the concentration of dextramabs via photometric analysis the extinction coefficient of DBCOVal-Cit-PAB-MMAE 19 was determined ( Figure S15 ). The slope of the graph equals the molar extinction coefficient.
Synthesis of compounds 1.3.1 General remarks
Reactions were performed at room temperature and atmospheric pressure unless mentioned otherwise. desalting columns following the instruction of the supplier. 
Synthesis of dextran-N-Boc-cadaverine 3
According to the literature in a 15 mL reaction tube dextran (1 eq) was dissolved in 2-5 mL 0.05 M borate buffer pH 8.2, N-Boc-cadaverine 1 (25 eq) and NaBH3CN (15.9 eq) was added. [4] The reaction mixture was stirred at darkness for 72 h at 30 °. Product was precipitated in cold methanol and washed three times with 30 mL MeOH and dried. The product was dissolved in water and purified, using disposable PD10 desalting columns, following the instruction of the supplier. After freeze-drying a pure white powder was obtained.
Quantification of reaction progress was determined by 1 H NMR spectrometry as described in the literature. [4] [5] 
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